Using MRI to dynamically measure glucose level changes in the brain lymphatic system may help to identify Alzheimer’s disease at early stages, according to joint research from City University of Hong Kong (CityU) and Johns Hopkins University.
“The tricky part of identifying Alzheimer’s disease is that early abnormalities, such as the emergence of protein plaques, are similar to normal ageing in the human brain,” says Kannie Chan Wai-yan, PhD, associate professor of department of biomedical engineering at CityU. “Patients diagnosed with symptoms, in which deposition of plaques are found in their brain hampering the cognitive function, are most likely already in the middle or late stage of the disease. Actually, pathologies in the brain happened 15 or 20 years before the symptoms appear.”
Recent findings have shown that abnormal clearance of waste in the glymphatic system—the lymphatic system in the brain—is one of the hallmarks of early Alzheimer’s disease. The glymphatic system is a drainage-like system for cerebrospinal fluid to flow through the brain tissue called brain parenchyma, thus facilitating efficient clearance of solutes such as glucose and protein waste from the brain.
Currently, glucose uptake and metabolism can be assessed by imaging with PET in hospitals. However, the PET scans with radioactive tracers are expensive, and its invasive nature has hindered its general clinical application. Moreover, patients cannot be scanned too frequently with radioactive tracers.
Chan’s team has spent almost 2 years looking for a better alternative. They have successfully developed a new imaging approach based on Chemical Exchange Saturation Transfer MRI (CEST MRI) to assess glucose uptake and clearance in the glymphatic system of mice brains noninvasively. “CEST MRI has been used in the diagnosis of brain tumors. This is the first time that it is used in assessing the function of glymphatic system,” says Chan.
Glucose: a tracer to assess the brain’s drainage system function
The team carried out the experiments using a 3T MRI animal scanner at CityU, the only of its kind in Hong Kong. They injected glucose into genetically modified mice with Alzheimer’s disease and healthy mice aged 6 months and 16 months. The dynamic response of glucose both in the cerebrospinal fluid and brain parenchyma were then measured simultaneously using the CEST MRI.
According to the MRI results, the team observed that the Alzheimer’s disease mice have shown significantly slower cerebrospinal fluid clearance rates than the age-matched healthy mice, which is consistent with previous neuropathological findings. “Clearance rates are reduced because of abnormalities in the brain’s drainage system,” says Chan.
Moreover, significantly higher glucose uptake was detected in brain parenchyma of the 6-month-old mice with Alzheimer’s disease compared to the healthy mice of the same age. For the 16-month-old mice with Alzheimer’s disease, significantly lower glucose uptake was found in both brain parenchyma and cerebrospinal fluid compared to the age-matched healthy mice. These results correspond with the previous research findings using other methodologies. These also serve as hallmarks to identify Alzheimer’s disease from normal ageing.
The imaging of glucose uptake and clearance in the cerebrospinal fluid and brain parenchyma enables the assessment of the brain glymphatic system. Importantly, abnormalities are detected at the early stage of Alzheimer’s disease when little neuropathology develops in the brain. The team believes this noninvasive assessment of the glymphatic system can serve as an imaging biomarker to reveal the early pathology in Alzheimer’s disease.
“By using glucose as a ‘tracer,’ our imaging method can sensitively detect the distinctive changes of glymphatic system function at the molecular level at an early stage of the disease, helping us to differentiate it from normal aging,” says Chan. “Besides, glucose is natural, biodegradable, and commonly used in hospitals, such as the glucose tolerance test. Using it as a contrast agent for MRI is noninvasive and safe.”
Low set-up cost and high translatability
Chan says that the new imaging method is compatible with the MRI machines commonly-used in clinics or hospitals, which means low set-up cost and technically easy to transfer into clinical application. “We have already obtained positive results on identifying changes in the tiny brains of mice at 3T (low magnetic field) scanner. We expect changes in human brains are more detectable at 3T clinical scanner since human brains are much larger,” says Chan.
Early identification and intervention of Alzheimer’s disease can halt or slow down its progression into a devastating stage that affects the daily life of patients. “This can help in reducing the care burden of the ageing society,” said Dr Chan, who anticipated clinical trial could be conducted in three years.
Find the study in Science Advances.
Featured image: The team carries out experiments on mice using the 3T MRI animal scanner at CityU, the only of its kind in Hong Kong. The left computer screen in the front shows vital signs such as the pulse and breathing pattern of the mouse, while the right one shows the images of its brain. Courtesy City University of Hong Kong